Lakefront Biotherapeutics NV
(LTS:0JXZ)
€
23.87
-0.060 (-0.25%)
Market Cap: 1.57 Bil
Enterprise Value: -664.17 Mil
PE Ratio: 2.65
PB Ratio: 0.48
GF Score: 51/100 Lakefront Biotherapeutics NV at Morgan Stanley Global Healthcare Conference Transcript
Sep 15, 2026 / 09:35PM GMT
Release Date Price:
€23.93
(+2.18%)
Judah Frommer
Morgan Stanley & Co Ltd - Analyst
All right. Good afternoon, everyone. Welcome to the final fireside of day 2 at Morgan Stanley's Global Healthcare Conference. I'm Judah Frommer, one of the SMid biotech analysts here. We're very excited to have Henry, Aaron, and Eric representing Lakefront.
Let me just get through a quick disclosure before we get started. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures.
Questions & Answers
Judah Frommer
Morgan Stanley & Co Ltd - Analyst
All right. With that, the team's been leading Lakefront through quite a transformation. So before we dive in, maybe give the audience an intro to the company and your focus since taking the helm last summer.
Henry Gosebruch
Lakefront Biotherapeutics NV - Chief Executive Officer, Executive Director
Great. Well, we're delighted to be here
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot